How long does the effect of rasagiline last? How many years?
Rasagiline As a monoamine oxidaseB (MAO-B) inhibitor, it is widely used in the treatment of Parkinson's disease (PD), especially in early monotherapy or in combination with levodopa, showing good results. Regarding the question about the duration of its drug effect, the simple answer should not be based on "a few years", because the persistence of rasagiline's drug effect depends more on the individual disease progression rate, medication compliance and combination treatment strategy.
From a pharmacological perspective, rasagiline irreversibly inhibitsMAO-B, thereby reducing the decomposition of dopamine in the brain, thereby delaying the progression of Parkinson's disease symptoms. The drug's MAO-B inhibitory effect usually lasts for at least 24 hours after oral administration once daily, so even if a short-term missed dose occurs, its inhibitory effect still has a certain "residual activity." This continuous mechanism ensures that patients maintain relatively stable symptom control during long-term medication.

In terms of long-term treatment, clinical practice shows that the improvement of motor symptoms with rasagiline can be maintained for many years. A large amount of literature shows that continuous use of rasagiline for more than two years can still maintain the control effect on core symptoms such as tremor, stiffness and bradykinesia. Especially when intervened early in the course of the disease, its neuroprotective potential may help delay the progression of the disease. However, it must be emphasized that this long-term benefit can only be achieved with regular review and individualized dose adjustment.
Although rasagiline does not cure Parkinson's disease, its effects in maintaining quality of life and delaying motor complications often last for years or longer. To sum up, the efficacy of rasagiline not only remains stable during daily dosing, but also has outstanding persistence under long-term treatment. However, the specific years still need to be comprehensively evaluated based on individual circumstances.
Reference materials:https://www.azilect.com/
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)